Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use
about
sameAs
Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American CoReview of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus ReportNon-Steroidal Anti-Inflammatory Drugs and Aspirin Therapy for the Treatment of Acute and Recurrent Idiopathic PericarditisEsomeprazole and aspirin fixed combination for the prevention of cardiovascular eventsProton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuriesGastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatmentGuidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapyConcomitant use of buffered and enteric-coated low-dose aspirin products and antisecretory drugsA clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-steroidal anti-inflammatory drugsRole of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug usersUpper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs - a 6-year analysis and comparison with non-steroidal anti-inflammatory drugsPractical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDsPrevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirinUpper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: where we are now?Upper gastrointestinal bleeding associated with antiplatelet drugsPeptic ulcer disease todayPrimary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national surveyThe prevalence of risk factors for gastrointestinal complications and use of gastroprotection among persons hospitalized for cardiovascular diseaseThe prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) studyPreventing recurrent ulcer bleeding. Switch from acetylsalicylic acid to clopidogrel or add esomeprazole?Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tractTreatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleedingPrevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategiesMy health: whose responsibility? Low-dose aspirin and older peopleShould we eradicate Helicobacter pylori in non-steroidal anti-inflammatory drug users?Effect of cyclo-oxygenase inhibitors on Helicobacter pylori susceptibility to metronidazole and clarithromycinShould we eradicate Helicobacter pylori infection in patients receiving nonsteroidal anti-inflammatory drugs or low-dose aspirin?The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitorIncidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery diseaseOptimizing cardiovascular and chemopreventive benefits of aspirin: what role for the proton-pump inhibitors?Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulantsAspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.Efficacy of Albis for the Prevention of Gastric Mucosal Injury Concomitant with the Use of Low-Dose Aspirin: A Prospective, Randomized, Placebo-Controlled Study.Diabetes and cardiovascular disease: from evidence to clinical practice - position statement 2014 of Brazilian Diabetes Society.Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks.Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale.Risk factors and therapeutic response in Chinese patients with peptic ulcer disease.Effect of a Proton Pump Inhibitor on Tumor Bleeding Prevention in Unresectable Gastric Cancer Patients: a Double-Blind, Randomized, Placebo-Controlled Trial
P2860
Q22241289-BBA450D8-E341-43AB-8EAE-CE2771D45BF8Q22241777-E3DE597D-ADD0-41D5-8E7A-BCCC72A0482BQ24674636-CE3EEE49-A17F-4822-BAB3-0891C522F06BQ26749687-4C1B6AF6-A69E-47E1-82EE-84B04E1246B7Q26995752-0499A6D1-17DB-4D04-9346-55A57C0CAAD1Q27004834-B112C99C-DF26-436D-9E82-8B7F5A909AEEQ27027977-0FA9524B-1BE2-4740-819C-740FECF8C7B6Q28166768-08E287F1-93DA-4A77-97B7-3C2CC8D2F894Q28168123-41F5E963-1AB8-49C6-865A-44AC00F10717Q28176840-F03623F0-9DA3-4CF4-8DC9-D9926FD60E14Q28182449-2FAE8DCC-7869-423F-BD6A-24DBE5B03C15Q28186823-1BF4B917-4434-4C98-B905-72EAC9CF0812Q28191928-1A3F56ED-6BB1-46D7-8BE1-5DDA609472EDQ28192701-A8873DAC-FFE0-4DF6-A8D0-788A434A6CFBQ28193564-52328B3C-CDE5-45DA-A56D-33B3D0EAA1B8Q28194354-9A80C1C0-AB4E-4BE0-8232-5E84D742BFBAQ28194844-7BC40922-5039-480F-A351-E6469EEB0900Q28195079-B7EF9F5A-4B47-4ED8-9D40-E4AFE621ABE8Q28195971-BC80A95B-ECC9-45AD-81FD-FFEAB99715FAQ28196518-262CAEBB-E64B-40AE-B1F2-9266C4090941Q28196797-D923DC46-3BDB-4C94-9521-C8788F31CED9Q28196810-61C6E8A0-F4DB-4096-A52E-99225CB796F0Q28196933-ABA4E6F6-4B8B-4A97-BC52-1351326FD638Q28198718-12A66CC9-20D2-46AE-A8A5-10A476BE3BE9Q28200569-2D36654E-8A04-4CEE-B83E-7A7C4AF64896Q28201631-AFCA61C2-F772-43F9-9BB7-7911146B4313Q28211894-45DF6C76-2CC2-4B2E-962C-1F9A7F4AA90AQ28212423-B7B3094C-B163-455D-9B34-C86365FC09F7Q28213638-2B93646A-CC7F-48EF-8D7D-9E5B01A9E4ADQ28217400-B4CB7C35-76DB-4539-B8CA-0DB22E3B1E49Q28218326-2C43F6B4-5F44-4B33-ACDD-814B163FB995Q28218738-50091883-BA52-480F-8DBE-463E12D7F45CQ28219972-8621671B-D9E7-491A-BD57-86DBC9F1A8F9Q30457290-639911EA-C5EF-4D77-94CD-F54051F8619AQ33583991-664662BC-4163-4DBB-88AD-88FD6E392EECQ33647298-E6A1B21C-5A74-4AB8-8F7D-9EC83E37C8F0Q33678007-B3CC37C8-554A-4027-9194-37BE0EEB5982Q33698340-E6D9A0A1-2770-40A5-A421-D7D0451247EFQ33812202-60B41A55-AA38-423C-8095-AEF80A8EB4C4Q33849286-6B34E792-F178-451E-AB47-E7C7E02F147E
P2860
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Lansoprazole for the preventio ...... long-term low-dose aspirin use
@ast
Lansoprazole for the preventio ...... long-term low-dose aspirin use
@en
Lansoprazole for the preventio ...... long-term low-dose aspirin use
@nl
type
label
Lansoprazole for the preventio ...... long-term low-dose aspirin use
@ast
Lansoprazole for the preventio ...... long-term low-dose aspirin use
@en
Lansoprazole for the preventio ...... long-term low-dose aspirin use
@nl
prefLabel
Lansoprazole for the preventio ...... long-term low-dose aspirin use
@ast
Lansoprazole for the preventio ...... long-term low-dose aspirin use
@en
Lansoprazole for the preventio ...... long-term low-dose aspirin use
@nl
P2093
P3181
P356
P1476
Lansoprazole for the preventio ...... long-term low-dose aspirin use
@en
P2093
Annie O O Chan
Benjamin C Y Wong
Ching Lung Lai
George K K Lau
Kam Chuen Lai
Kent Man Chu
Man Fung Yuen
Shiu Kum Lam
Wai Man Wong
P304
P3181
P356
10.1056/NEJMOA012877
P407
P577
2002-06-27T00:00:00Z